A review on toxicities of T-cell engager-based therapies in solid tumors
T-cell engager (TCE)-based therapies represent an emerging and rapidly expanding class of immunotherapies in oncology. Initially developed for hematologic malignancies, TCEs are now entering the field of solid tumors. To date, two agents have received regulatory approval in this setting: Tebentafusp for metastatic uvea...